Regional response of lymphatic tissue in bronchogenic cancer
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
6420126
Knihovny.cz E-zdroje
- MeSH
- akryláty terapeutické užití MeSH
- alkalická fosfatasa metabolismus MeSH
- bronchogenní karcinom farmakoterapie enzymologie imunologie MeSH
- cisplatina terapeutické užití MeSH
- lidé MeSH
- lymfocyty imunologie MeSH
- nádory plic farmakoterapie enzymologie imunologie MeSH
- protinádorové látky terapeutické užití MeSH
- tvorba rozet MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- akryláty MeSH
- alkalická fosfatasa MeSH
- cisplatina MeSH
- Penberol MeSH Prohlížeč
- protinádorové látky MeSH
The limiting factors in the treatment of bronchogenic cancer consist, from the bronchological point of view, in the possibility to estimate the advanced macromorphological stage of the disease with the determination of the degree of the affection of regional intrathoracic nodes. By the perbronchial route it is possible to obtain also a sufficient amount of material from unaffected nodes for purposes of testing their function. The testing of the spontaneous E-rosette formation is shortened, with the use of this method, by three quarters of an hour, but the possibility of obtaining a sufficient quantity of lymphocytes by the perbronchial puncture with the use of a fine needle is on average smaller than 50% in all types of bronchogenic cancer. It will be probably possible to introduce gradually also other immunological and biochemical methods of testing the function of the regional lymphatic tissue, as confirmed by the authors' experiences with immunological and biochemical investigations of bronchial washings with the use of 4 ml of the saline washing liquid. Experiences are thus far only preliminary and not unequivocal. Different alkaline under study, with better treatment results in patients treated with Cis-Platine, indicate phosphatase levels in patients with Penberol and Cis-Platine monotherapy in the series under study, with better treatment results in patients treated with Cis-Platine, indicate the possibility of using a further limiting aspect of cytostatic therapy.